Thomas J. Lynch Jr., MD, is president and director of the Fred Hutchinson Cancer Center, where he sets the center’s strategic direction, oversees centerwide initiatives, and represents Fred Hutch to major partners and governmental bodies.
He also directs the Fred Hutch/University of Washington/Seattle Children’s Cancer Consortium and is principal investigator of its Cancer Center Support Grant. A widely respected oncologist and scientist, Dr. Lynch is an experienced leader of National Cancer Institute-designated comprehensive cancer centers. He became Fred Hutch’s sixth president in February 2020, having most recently served as chief scientific officer of Bristol-Myers Squibb.
Earlier in his career he was CEO of the Massachusetts General Physicians Organization, director of the Yale Cancer Center, physician-in-chief at Yale’s Smilow Cancer Hospital, chief of hematology-oncology at Massachusetts General Hospital, and a professor of medicine at Harvard Medical School. Dr. Lynch was part of the first research team to discover how targeted therapies could dramatically change outcomes for lung cancer patients with mutations in the EGFR, or epidermal growth factor receptor, gene. He is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, and the International Association for the Study of Lung Cancer.